<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01046578</url>
  </required_header>
  <id_info>
    <org_study_id>WHIRL-08-1200</org_study_id>
    <nct_id>NCT01046578</nct_id>
  </id_info>
  <brief_title>Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women</brief_title>
  <official_title>Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, open label randomized clinical trial designed to examine ovarian follicular
      dynamics following attempted atresia induction during the late follicular and early luteal
      phase of the menstrual cycle using an aromatase inhibitor.

      We hypothesize that administration of an aromatase inhibitor (AI) at biologically important
      times of the natural menstrual cycle will cause ovulatory failure in women with preovulatory
      follicles and failure of luteogenesis in women who have recently ovulated. It is proposed
      that atresia of the dominant follicle and formation of anovulatory structures will be
      associated with arrested endometrial development and a shortened interval to menstrual
      bleeding (3 days). We anticipate that this will provide us with information to facilitate the
      development of a new method for emergency contraception and a greater understanding of human
      folliculogenesis.

      The rationale for the proposed research project is based on the ovarian synchronization
      concepts developed and documented in the bovine model in the Reproductive Science and
      Medicine Research group at the University of Saskatchewan combined with novel human ovarian
      wave concepts of folliculogenesis first elucidated in the Women's Health Imaging Research
      Laboratory (WHIRL) in the Department of Obstetrics, Gynecology and Reproductive Sciences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In clinical practice emergency contraception (EC) intends to suppress follicular development,
      ovulation, or the ability of a conceptus to implant. Exogenous steroids, estrogen and
      progestin, are used in various formulations to accomplish the suppression. Though EC are now
      available 'over-the-counter' in Canada and many countries around the world; the ovarian
      response is unpredictable and EC do not inhibit ovulation at the most critical times of the
      menstrual cycle. In 2002 approximately 120,000 of 450,000 pregnancies in Canada ended in
      elective pregnancy termination. In the US 49% of the 3.5 million annual pregnancies were
      unintended and 54% of the unintended pregnancies resulted in elective termination.

      Current hormonal contraceptive regimens, pre and post coital, are based on the traditional
      theory of follicular development that states that a single group of antral follicles is
      recruited in the late luteal phase for growth. Recent documentation has show that human
      ovarian folliculogenesis occurs in a 2-3 wave like pattern during a menstrual cycle. Wave
      emergence has been documented to occur in the early luteal phase with the final wave being
      ovulatory. The new model of follicular wave dynamics is well established and supported by
      experimental evidence in the bovine and equine models.

      Traditionally these hormonal medications are taken 72 to 120 hours after known or suspected
      barrier contraception failure or unprotected intercourse. The two standard steroidal EC
      methods are Plan BTM, containing of 0.75 mg levonorgestrel (LNG), and the Yuzpe method,
      containing 0.1 mg ethinyl estradiol (EE) and 0.5 mg LNG. Ovarian follicular development and
      ovulation in women have been studied after EC use; however, the mechanisms underlying
      follicular growth, regression, and ovulation during EC use remain poorly elucidated. The
      mechanism of action differs with each EC regimen as well as being dependent upon the relative
      timing between dosing, intercourse, and ovulation. Previous studies have shown that EC are
      most effective if used when the dominant follicle diameter is small (4 to 5 days prior to
      ovulation), however, during this time interval intercourse is less likely to result in
      pregnancy whether or not EC were administered.

      All current emergency contraception (EC) options are guided by the traditional theory of
      follicular development. Based on the findings of an unpredictable response of the ovaries to
      EC treatment, the occurrence of ovulation after treatment with EC, and findings of follicle
      growth in a 2-3 wave pattern, we need to reconsider the phase of the menstrual cycle and the
      treatment given for emergency contraception.

      Aromatase inhibitors (AI) prevent the enzymatic conversion of androgens to estrogens. This
      significantly lowers serum estrogen levels. AI have been administered around the time of
      menses for ovulation induction and ovulation was seen to follow 10 to 12 days later. The
      rationale for inducing atresia of dominant follicles stems from this observation. Acute
      estradiol deprivation should theoretically initiate atresia of all viable follicles in the
      cohort resulting in the emergence of a new follicle wave without an ovulation event
      occurring.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fate of the dominant follicle or luteal structure</measure>
    <time_frame>40-45 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>interval to follicle wave emergence, and interval to selection of a dominant follicle</measure>
    <time_frame>40-45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endometrial thickness/pattern</measure>
    <time_frame>40-45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ultrasonographic image attributes of follicular structures that develop after administration of treatment</measure>
    <time_frame>ongoing</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Fertility</condition>
  <arm_group>
    <arm_group_label>Single Dose 12mm follicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose 18mm follicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Post Ovulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 post ovulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi Dose 12mm follicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi Dose 18mm follicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi Dose Post Ovulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 hours post ovulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention given, followed for course of study on a natural cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter</description>
    <arm_group_label>Single Dose 12mm follicle</arm_group_label>
    <other_name>Femara (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter</description>
    <arm_group_label>Single Dose 18mm follicle</arm_group_label>
    <other_name>Femara (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed</description>
    <arm_group_label>Single Dose Post Ovulation</arm_group_label>
    <other_name>Femara (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed</description>
    <arm_group_label>Multi Dose Post Ovulation</arm_group_label>
    <other_name>Femara (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter</description>
    <arm_group_label>Multi Dose 18mm follicle</arm_group_label>
    <other_name>Femara (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter</description>
    <arm_group_label>Multi Dose 12mm follicle</arm_group_label>
    <other_name>Femara (TM)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects of childbearing potential with normal reproductive function;

          -  Women between 18 and 35 years of age;

          -  Normal Body Mass Index (18-30);

          -  Are na√Øve to OC or have discontinued OC at least 2 months prior to study entry;

          -  Subject has signed the informed consent form;

          -  Subject is in good general health as confirmed by medical history and physical
             examination

        Exclusion Criteria:

          -  Irregular menstrual cycles;

          -  Any contraindication for oral contraception use;

          -  Known hypersensitivity to Letrozole and co-administered medications;

          -  Evidence of Polycystic Ovary Syndrome (PCOS) or Endometriosis;

          -  History of pituitary tumor;

          -  Pregnancy (suspected or diagnosed) or lactation;

          -  HIV, HBV, HCV infection;

          -  Vaginal infection;

          -  Abnormal ECG;

          -  Abnormal lab tests for blood profile, liver function and renal function;

          -  Uncontrolled diabetes and blood pressure;

          -  History or suspicion of alcohol or drug abuse;

          -  History of severe mental disorders;

          -  Participation in an investigational drug trial in the 30 days prior to selection;

          -  A subject who exhibits a disorder that is a contraindication to steroid hormonal
             therapy, including, for example, the following conditions:

          -  History of/or actual thrombophlebitis or thromboembolic disorders.

          -  History of/or actual cerebrovascular disorders.

          -  History of/or actual myocardial infarction or coronary arterial disease.

          -  Active liver disease or history of/or actual benign or malignant liver tumors.

          -  Known or suspected carcinoma of the breast.

          -  Known or suspected oestrogen-dependent neoplasia.

          -  Undiagnosed abnormal vaginal bleeding

          -  Any ocular lesion arising from ophthalmic vascular disease, such as partial or
             complete loss of vision or defect in visual fields.

          -  Smokes.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger A Pierson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donna R Chizen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2010</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Roger Pierson</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Folliculogenesis</keyword>
  <keyword>Letrozole</keyword>
  <keyword>Aromatase Inhibitor</keyword>
  <keyword>Estrogen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

